References

69612
Selected Publications and WCC-Presentations ON Aspartyl-(asparaginyl)-β-hydroxylase (AABH / ASPH / HAAH )

  1. Mahmood Moshiri, Hasan Monhemi, Kiarash Moshiri, Reza Nazari, Arsha Moshiri, Mohammad Pishrochi, World Congress on Precision & Personalized Medicine – HYBRID EVENT , Theme: Latest Innovations in Genetics, Genomics and Precision Medicine, August 22-23, 2022, Rome – Aurelia, Roma, Italy (WCPPM-2022), Early Diagnosis of Cancer, Aspartyl (Asparaginyl) β-Hydroxylase (AABH), a predictive Biomarker, Diagnostic Serum Immunoassay, Cancer Imaging, Cancer Therapeutic Vaccine, Nano-Particles and Personalized Medicine.(Keynote Speech).
  2. Arsha Moshiri MDS, Hamed Pashaei MD, Kiarash Moshiri MD, Hassan Monhemi PhD Reza Nazari PhD, ASCO 2022, Genitourinary Cancers Symposium, February 17-19, 2022, San Francisco, CA, USA, abstract      # 349531, Aspartyl (Asparaginyl) β-hydroxylase (AABH) as a serum biomarker for prostate cancer, to identify prostate cancer, regardless of PSA level.
  3. Mahmood Moshiri, Kiarash Moshiri, Reza Nazari, Mohammad Pishrochi, Arsha Moshiri, Hassan Monhemi, ASCO 2022 Gastrointestinal Cancers Symposium, January 20-22, 2022, San Francisco, CA, USA, Abstract #352146, Colorectal cancer biomarker, AABH (Aspartyl [Asparaginyl] β- hydroxylase), a companion imaging and treatment strategy.
  4. Kiarash Moshiri MD, Mahmood Moshiri MD , ASCO-SITC, Immuno-Oncology Symposium, Feb 6-8, 2020, Orlando, FL, USA., Abstract #278569 AABH( aspartyl (asparaginyl) β-hydroxylase) as a serum biomarker for Breast Cancer.
  5. Mahmood Moshiri MD, Kiarash Moshiri MD, Arsha Moshiri MDS ASCO-SITC, Immuno-Oncology Symposium, Feb 6-8, 2020, Orlando, FL, USA., Abstract #278563 Aspartyl (Asparaginyl) β-Hydroxylase (AABH), A Serum Biomarker for Lung Cancer.
  6. Kiarash Moshiri MD, Mahmood Moshiri MD , ASCO-SITC, Genitourinary Cancer Symposium, Feb 13-15, 2020, San Francisco, CA, USA, Abstract #281375 , Early Diagnosis of Prostate Cancer, AABH(Aspartyl (Asparaginyl) β-Hydroxylase) a predictive Biomarker, A Serum Immunoassay and Personalized Medicine.
  7. Kiarash Moshiri MD, Mahmood Moshiri MD; AABH (Aspartyl (Asparaginyl) β-Hydroxylase) a predictive Biomarker, A Serum Immunoassay and Personalized Medicine. Abstract #281375, ASCO, GENITO-URINARY CANCER SYMPOSIUM, #GU20, San Francisco, CA, USA, February, 13-15, 2020.
  8. Kiarash Moshiri MD, Mahmood Moshiri MD; AABH (Aspartyl (asparaginyl) β-hydroxylase) as a serum biomarker for Breast Cancer. Abstract #278563, ASCO-SITC, CLINICO-IMMUNO-ONCOLOGY SYMPOSIUM, #IMMUNOONCO20, Orlando, Florida, USA, February, 6-8,2020.
  9. Kiarash Moshiri MD, Mahmood Moshiri MD, Arsha Moshiri MDS, ; AABH ( aspartyl (asparaginyl) β-hydroxylase) as a serum biomarker for Lung Cancer. Abstract #278563, ASCO-SITC, CLINICO-IMMUNO-ONCOLOGY SYMPOSIUM, #IMMUNOONCO20, Orlando, Florida, USA, February, 6-8,2020.
  10. Mahmood Moshiri, K. Moshiri, M.H. Sekhavati, Hassan Monhemi, Arsha Moshiri; AABH (Human Aspartyl (Asparaginyl) β-Hydroxylase), A Serum Biomarker for Lung Cancer, BIT’s 17th ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERYDCIENCE AND TECHNOLOGY, KYOTO, JAPAN , JULY, 25-28 , 2019.
  11. Mahmood Moshiri, K. Moshiri, M.H. Sekhavati, Hassan Monhemi, Arsha Moshiri; AABH (Human Aspartyl (Asparaginyl) β-Hydroxylase), A Serum Biomarker for Prostate Cancer, BIT’s 17th ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERYDCIENCE AND TECHNOLOGY, KYOTO, JAPAN , JULY, 25-28 , 2019.
  12. Mahmood Moshiri, K. Moshiri, M.H. Sekhavati, Hassan Monhemi, Arsha Moshiri; AABH (Human Aspartyl (Asparaginyl) β-Hydroxylase), A Serum Biomarker for Colon Cancer, BIT’s 17th ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERYDCIENCE AND TECHNOLOGY, KYOTO, JAPAN , JULY, 25-28 , 2019.
  13. Mahmood Moshiri, Kiarash Moshiri, Arsha Moshiri, Hassan Monhemi, Mohammad Hadi Sekhavati, Aspartyl (Asparaginyl) ß Hydroxylase (AABH) is a serum bio-marker for Prostate Cancer and can identify Prostate Cancer, regardless of PSA level. GENITOURINARY CANCER SYMPOSIUM, , SAN FRANCISCO, USA, FEBRUARY, 8-10,, 2018.
  14. Mahmood Moshiri, Kiarash Moshiri, Yasamin Farbod, Arsha Moshiri, Mohammad Hadi Sekhavati; Aspartyl (Asparaginyl) β-Hydroxylase AABH as a serum bio-marker for Colorectal Cancer. Clinical Immuno-Oncology Symposium, ASCO-SITC, San Francisco, USA , January 25-27, 2018.
  15. ASCO ARTICLE CITATION:DOI: 10.1200/JCO.2018.36.6_suppl.10 Journal of Clinical Oncology – published online before print February 26, 2018 , Aspartyl (Asparaginyl) ß hydroxylase (AABH) as a serum bio-marker for prostate cancer to identify prostate cancer, regardless of PSA level. Mahmood Moshiri, Kiarash Moshiri, Arsha Moshiri, Hassan Monhemi, Mohammad Hadi Sekhavati.
  16. Mahmood Moshiri, Kiarash Moshiri, Mohammad H. Sekhavati, Hassan Monhemi, Yasamin Farbod, Arsha Moshiri Early Diagnosis of Cancer, AABH (Aspartyl (Asparaginyl) β-Hydroxylase) a predictive Biomarker, A Diagnostic Serum Immunoassay and Personalized Medicine. (KEYNOTE SPEECH), BIT’S ANNUAL CONGRESS OF MOLECULAR MEDICINE 2017, X’IAN, CHINA , SEPTEMBER 25-28 , 2017.
  17. Mahmood Moshiri, Kiarash Moshiri, Mohammad H. Sekhavati, Hassan Monhemi, Yasamin Farbod, Arsha Moshiri Cancer Biomarker, AABH (Aspartyl (Asparaginyl) β- Hydroxylase), a Companion Imaging and Diagnostic Strategy., BIT’S ANNUAL CONGRESS OF MOLECULAR MEDICINE 2017, X’IAN, CHINA , SEPTEMBER 25-28 , 2017.
  18. Mahmood Moshiri, Kiarash Moshiri, Arsha Moshiri, Hassan Monhemi, Mohammad Hadi Sekhavati,  Aspartyl (Asparaginyl) ß Hydroxylase (AABH) is a serum bio-marker for Prostate Cancer and can identify Prostate Cancer, regardless of PSA level. GENITOURINARY CANCER SYMPOSIUM, FEBRUARY, 8-10,, 2018, SAN FRANCISCO, USA.
  19. Mahmood Moshiri, Kiarash Moshiri, Yasamin Farbod, Arsha Moshiri, Mohammad Hadi Sekhavati; Aspartyl (Asparaginyl) β-Hydroxylase AABH as a serum bio-marker for Colorectal Cancer. Clinical Immuno-Oncology Symposium, ASCO-SITC, January 25-27, 2018, San Francisco, USA.
  20. Mahmood Moshiri ,*, Kiarash Moshiri, Saeed Babaei , M. S. Lebowitz , S. F. Roberts , H. Ghanbari “EARLY DIAGNOSIS OF CANCER: AABH-A PREDICTIVE BIOMARKER, A SERUM IMMUNOASSAY AND PERSONALISED MEDICINE” Global Biomarker Conference, Toronto, Canada, 2013.
  21.  M. A. Semenuk and H. A. Ghanbari “Serum Biomarkers Carcinoembryonic Antigen (CEA) and Human Aspartyl (Asparaginyl) Beta Hydroxylase (AABH) Compared in Normal Volunteers, Smokers, and Lung Cancer Patients.” American Association for Cancer Research Annual Meeting, Washington, DC (2013).
  22.  M. Moshiri,* M. S. Lebowitz, S. F. Roberts, Abbas Zokaei-Ashtiani, H. Ghanbari “Human Aspartyl (Asparaginyl) β-Hydroxylase (AABH) Levels as an Indicator for Patients at Risk for Prostate Cancer”. BIT’s 3rd Annual World Congress of Biomarkers, Guangzhou, China -2012.
  23.  M. Moshiri,* M. S. Lebowitz, S. F. Roberts, Abbas Zokaei-Ashtiani, H. Ghanbari “ AABH (Human Aspartyl (Asparaginyl) β-Hydroxylase), a Cancer Tumor Marker, For Early cancer Detection”. 5th Annual World Congress and Exposition of Molecular Diagnostics, Guangzhou, China, 2012.
  24. M. Moshiri, M. S. Lebowitz , S. F. Roberts 2, C. J. Panchal, A. Zokaei-Ashtiani, H. Ghanbari “Cancer Biomarker, AABH(Human Aspartyl (Asparaginyl) â-Hydroxylase), a Companion Diagnostic Strategy”, 5th Oncology Biomarkers: From Discovery to Validation, Zurich, 2012.
  25.  M. Moshiri, M. S. Lebowitz , S. F. Roberts 2, C. J. Panchal, A. Zokaei-Ashtiani, H. Ghanbari “EARLY DIAGNOSIS OF CANCER: AABH-BASED SERUM IMMUNOASSAY”, 2012-World Cancer Congress, UICC, Montreal, ON, Canada, (2012).
  26.  M. Moshiri ,*, M. S. Lebowitz , S. F. Roberts , A. Zokaei-Ashtiani, C. J. Panchal, “AABH-BASED MONITORING OF CANCER REMISSION/RECURRENCE, World Cancer Congress,UICC, Montreal, ON, Canada, (2012).
  27.  Biswajit Biswas, Marjan Alaghmand, Illham Bensmail, Carl Meril, and Hossein A. Ghanbari.”Dentritic Cell-Based Center Therapeutic Vaccine targeting AABH Using nano-Particles To Overcome Tolerance and Avoid Auto-Immune Response.” International Society for Biological Therapy of Cancer (ISBTc) 25th Annul Meeting, Bethesda, MD( 2009).
  28. S.N. Keith, P.J. Harris, A.F. Repoli, M. Semenuk, H.A. Ghanbari and M.S. Lebowitz. The Serum Biomarker AABH Identifies Prostate Cancer In Individuals With Low PSA Values. 2008 Genitourinary Cancers Symposium. San Francisco, CA. (2008).
  29.  D. Khayat, R. Mouawad, M. S. Lebowitz, and H. A. Ghanbari. “Serum AABH Level in NSCLC is a Diagnostic and Could be a Predictive Factor of Clinical Response.” 44th ASCO Annual Meeting, Chicago, IL (2008).
  30.  Ilham Bensmail, Michael S. Lebowitz and Hossein A. Ghanbari. “Anti-AABH antibodies block leukemic cell activity via down-regulation of the Notch signaling pathway.” AACR Annual Meeting 2008, San Diego, CA (2008).
  31. Hossein A. Ghanbari and Michael S. Lebowitz. “In vivo efficacy of PAN-622: An All Human Sequence Monoclonal Antibody Targeted at AABH.” AACR Annual Meeting 2008, San Diego, CA (2008).
  32. S.N. Keith, P.J. Harris, A.F. Repoli, M. Semenuk, H.A. Ghanbari, and M.S. Lebowitz. ” The Serum AABH identifies Prostate Cancer in individuals with low PSA values”. 2008 Genitourinary Cancer Symposium, February 2008, San Francisco.
  33. Hossein Ghanbari, Angela F. Repoli, Mark Semenuk, Ilham Bensmail, Audrey A. Vasauskas and Michael S. Lebowitz. “AABH-based Serum Cancer Test: A Companion Diagnostic in Cancer Therapeutics.” International Congress on Anti Cancer Treatment, Paris, France. (2008).
  34.  Hossein Ghanbari, Valery Nelson, Angela F. Repoli, and Michael S. Lebowitz. “PAN-622, An All-Human Anti-Cancer Antibody Drug Candidate Targeted to AABH: A Cytostatic Approach to Cancer Therapy. International Congress on Anti Cancer Treatment, Paris, France. (2008).
  35.  Michael S. Lebowitz, Angela F. Repoli, Mark Semenuk, Ilham Bensmail and Hossein A. Ghanbari. “Integration of the Cancer Biomarker, AABH, into a Companion Diagnostic Strategy.” Oncology Biomarkers: From Discovery to Validation. San Francisco, CA (2008).
  36. H.A. Ghanbari, A.F. Repoli, M. Semenuk, P.J. Harris and M.S. Lebowitz. AABH as a serum biomarker for colorectal Cancer. An AACR Special Conference in Cancer Research―Advances in Colon Cancer Research Cambridge, MA (2007).
  37.  Ghanbari, HA; Repoli, AF; Semenuk, M; Harris, PJ; Lebowitz, MS. AABH as a Serum Biomarker for Breast Cancer. An AACR Special Conference in Cancer Research―Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego, CA (2007).
  38. Semenuk, M; Repoli, AF; Lebowitz, MS; Harris, PJ; Ghanbari, HA. AABH is a Serum Biomarker for Lung Cancer. The Second Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment, Atlanta, GA (2007).
  39. D’Amico, MD; Roberts, SF; Lebowitz, MS; Ghanbari, HA. Use of anti-AABH antibodies in Cancer therapy: specific delivery of cytotoxic agents. AACR Annual Meeting 2007, Los Angeles, CA (2007).
  40. Otahalova, E., Lebowitz, M.L., Ghanbari, H.A. “Identification of Responders and Non-Responders to Imatinib Prior to Treatment.” 18th EORTC-NCI-AACR International Conference on “Molecular Targets and Cancer Therapeutics, Prague, Czech Republic (2006).
  41. Ghanbari, H.A., Vasauskas, A.A., Bensmail, I., Lebowitz, M.L. “AABH is a Serum Biomarker for Prostate Cancer.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006).
  42. Lebowitz, M.L., Otahalova, E., Ghanbari, H.A. “A Novel Biomarker to Diagnose and Monitor Acute Myelogenous Leukemia.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006).
  43. Nelson, V.M., Finney, A.H., Drape, R.J., Bleck, G.T., Lebowitz, M.L., Ghanbari, H.A. “Manufacture of anti_AABH Antibodies as Potential Human Therapeutics.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006).
  44. A.H. Finney, M.W. D’Amico, S.F. Roberts, M.S. Lebowitz, H.A. Ghanbari. Surface Expressed AABH in Cancer Cells is an Internalizing Antigen. AACR 97th Annual Meeting, Washington, D.C. 2006.
  45. Yeung, A., Finney, A.H., Lebowitz, M.L., Ghanbari, K., Ghanbari, H.A., Wittrup, D.: “Isolation and Engineering of Biologically Active Human Single-Chain Antibody Fragments (Scfv) Against Human Aspartyl (Asparaginyl) β- Hydroxylase.” AACR—Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA. 
  46. Finney, A.H., Lebowitz, M.L., Vasauskas, A.A., Ghanbari, K., Nelson, V.M., and Ghanbari, H.A.: “Anti-Proliferative and Anti-Metastatic Activities of Monoclonal Antibodies to Human Aspartyl (Asparaginyl) β-Hydroxylase.” AACR— Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA.
  47. Vasauskas, A.A., Glass, L., Ghanbari, K., Lebowitz, M.L., Ranji, C., Maric, M., and Ghanbari, H.A.: “AABH as a Biomarker for Pancreatic Adenocarcinoma Using IHC, qRT-PCR and ELISA.” AACR—Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA.
  48. Audrey A. Vasauskas, Cyra M. Ranji, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Human Aspartyl (Asparaginyl) β-Hydroxylase is a Serum Biomarker of Breast, Ovarian, and Prostate Cancer. AACR 94th Annual Meeting, July 11-14 2003, Washington, DC. 
  49.  Lawrence Glass, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Differential Expression of ASPH Gene Encoding Human Aspartyl (Asparaginyl) β-Hydroxylase in Cancer Versus Normal Tissues. AACR 94th Annual Meeting, July 11-14 2003, Washington, DC.
  50. Wands, Jack R.; Tamaki, Seishu; Sepe, Paul; Maeda, Takashi; Lahousse, Stephanie; and de la Monte, Suzanne M. Antisense Oligonucleotide of Human Aspartyl (Asparaginyl) β-Hydroxylase Suppresses Migration of Human Cholangiocellular Cells. American Association for The Study of Liver Diseases – 52nd Annual Meeting November 9-13, 2001 Hepatology,: 34(4), Part II, pp. 267A, October 2001.
  51. Michael S. Lebowitz, Angela H. Finney, Valery M. Nelson, Audrey A. Vasauskas, Kasra Ghanbari, Alan H. Deutch and Hossein A. Ghanbari. Inhibition of Cancer Cell Proliferation, Motility and Invasiveness by Monoclonal Antibodies Specific for Human Aspartyl (Asparaginyl) β-Hydroxylase (AABH). AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 29-November 2,2001, Miami Beach, Florida.
  52. Michael A. Rosen, Kasra Ghanbari, Alan H. Deutch, and Hossein A. Ghanbari. Development of Cancer Immunodiagnostics Using Human Aspartyl (Asparaginyl) β-Hydroxylase (AABH) as a Biomarker. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 29-November 2, 2001, Miami Beach, Florida.
  53.  Kevin Scott Palumbo, Thomas King, Howard Safran, Jack R. Wands, Suzanne de la Monte. Potential Biomarkers for Detecting Pancreatic Carcinoma. Gastroenterology: 120, Number 5, A-161, 2001.
  54. S. Lahousse, P. Sepe, J. R. Wands, and S. M. de la Monte. Role of Aspartyl (Asparaginyl) β-Hydroxylase in Neuroblastoma Migration. 90th Annual Meeting of the United States & Canadian Academy of Pathology, Atlanta,Georgia, March 7, 2001.
  55. Xiaoqun Dong1,2, Qiushi Lin1,2, Arihiro Aihara3, Yu Li1, Chiung-Kuei Huang3, Waihong Chung3, Qi Tang1, Xuesong Chen1, Rolf Carlson3, Christina Nadolny1, Gregory Gabriel4, Mark Olsen5 and Jack Wands: “Aspartate Beta-Hydroxylase expression promotes a malignant pancreatic cellular phenotype” Oncotargets advanced publications Oct 2014.
  56. Tian Xue1 , Jing Su2 , Hongmin Li 1 and xiaoping xue: “Evaluation of AABH/humbug quantitative detection in the diagnosis of hepatocellular carcinoma” Oncology reports Wed, 01 Oct 2014.
  57. Steven Fuller, Solomon Stewart, Michael Lebawitz, Hossein Ghanbari: “Inhibition of human natural killer cell functional activity by human aspartyl –hydroxylase” Society for immunotherapy of Cancer Thu, 01 May 2014.
  58. Nisha Patel,1,9 Arif O. Khan,1,2,9 Ahmad Mansour,3 Jawahir Y. Mohamed,1 Abdullah Al-Assiri,4 Randa Haddad,3 Xiaofei Jia,5 Yong Xiong,5 Andre´ Me´garbane´,6 Elias I. Traboulsi,7 and Fowzan S. Alkuraya1 “Mutations in ASPH Cause Facial Dysmorphism, Lens Dislocation, Anterior-Segment Abnormalities, and Spontaneous Filtering Blebs” The American Journal of Human Genetics 94, 755–759, May 1, 2014.
  59. H. Yang, K. Song, T. Xue, X.P. Xue, T. Huyan, W. Wang and H. Wang “The distribution and expression profiles of human Aspartyl/Asparaginyl beta-hydroxylase in tumor cell lines and human tissues.” Oncology Reports, 24, 1257-1264, 2010.
  60. Y.A. Yeunga, A.H. Finneyb, I.A. Koyrakha, M.S. Lebowitzb, H.A. Ghanbarib, J.R. Wandsc and K.D. Wittrupd, “Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) β-hydroxylase.” Human Antibodies, 16, 163–176, 2007.
  61. F. Gundogan, G. Elwood, L. Longato, M. Tong, A. Feijoo, R.I. Carlson, J.R. Wands, S.M. de la Monte. “Impaired Placentation in Fetal Alcohol Syndrome.” Placenta 29, 148-157, 2008.
  62. Tracy Hampton. “New Screening Techniques Show Potential for Early Detection of Lung Cancer”. JAMA. 17, 298, 2007.
  63. Stephanie A. Lahousse, Jade J. Carter, Xaolai J. Xu, Jack R. Wands and Suzanne M. de la Monte. Differential growth factor regulation of Aspartyl-Asparagyl β hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biology, 7:41, 1-21, 2006.
  64. M.Chiara Cantarini, Suzanne M. De la Monte, Maoyin Pang, Ming Tong, Antonia D’Errico, Franco Trevisani and Jack R.Wands. “Aspartyl-Asparagyl β hydroxylase Over-Expression in Human Hepatoma is Linked to Activation of Insulin-Like Growth Factor and Notch Signaling Mechanisms.” Hepatology, 44:2, 446-457, 2006.
  65. G. Feldmann, J. Nattermann, H.D. Nischalke, M.Gorschluter, T. Kuntzen, G. Ahlenstiel, G. Ahlenstiel, T. Gerhardt, M. Wolff, T. Sauerbruch, U. Spengler, F.L. Dumoulin. “Detection of Human Aspartyl (Asparaginyl) Beta-Hydroxylas and Homeobox B7 mRNA in Brush Cytology Specimens from Patients with Bile Duct Cancer.” Endoscopy, 38:6, 604-609,
  66. Zhi-Hong Xian, Shu-Hui Zhang, Wen-Ming Cong, He-Xin Yan, Kui Wang, and Meng-Chao Wu. “Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma.” Modern Pathology 19: 280-286, 2006.
  67. Suzanne M. de la Monte, Seishu Tamaki, M. Chiara Cantarini, Nedim Ince, Marcus Wiedmann, Jade J. Carter, Stephanie A. Lahousse, Sophia Califano, Takashi Maeda, Takato Ueno, Antonia D’Errico, Franco Trevisani, Jack R. Wands. “Aspartyl-(asparaginyl)-β-hydroxylase Regulates Hepatocellular Carcinoma Invasiveness.” Journal of Hepatology: 44, 971-983, 2006.
  68. Takashi Maeda, Ken-ichi Taguchi, Shin-ichi Aishima, Mitsuo Shimada, Deborah Hintz, Nicholas LaRusso, Gregory Gores, Masazumi Tsuneyoshi, Keizo Sugimachi, Jack R. Wands, and Suzanne de la Monte. “Clinicopathological Correlates of Aspartyl (Asparaginyl) β-Hydroxylas Over-Expression in Cholangiocarcinoma.” Cancer Detection and Prevention: 28, 313-318, 2004.
  69. Eric P. Berthiaume, M.D., and Jack Wands, M.D. “The Molecular Pathogenesis of Cholangiocarcinoma.” Seminars in Liver Disease 24(2): 127-137, 2004.
  70. Gregory J. Gores. Editorial: “Cholangiocarcinoma: Preventing Invasion as Anti-Cancer Strategy.” Journal of Hepatology 38, 671-673, 2003.
  71. Takashi Maeda, Paul Sepe, Stephanie Lahousse, Seishu Tamaki, Munetomo Enjoji, Jack R. Wands, and Suzanne M. de la Monte. “Antisense Oligodeoxynucleotides Directed Against Aspartyl (Asparaginyl) ß-Hydroxylase Suppress Migration Of Cholangiocarcinoma Cells.” Journal of Hepatology: 38, 615-622, 2003.
  72. Michael J. Feldhaus, Robert W. Siegel, et al. „Flow-cytometric isolation of human antibodies from a non-immune Sacchoromyces cerevisiae surface display library.” Nature Biotechnology: 21, 163-170, 2003.
  73. Commentary on Wittrup paper. “Breaking the Affinity Ceiling for Antibodies and T Cell Receptors.” Proceedings of the National Academy of Sciences: 97(20), 10679-1068, 2000.
  74. Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. “Human aspartyl (asparaginyl) betahydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma.” Pancreas Jul; 25(1):39-44, 2002.
  75. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM. “Role of the aspartyl-asparaginylbeta-hydroxylase gene in neuroblastoma cell motility.” Lab Invest J: 82(7):881-91, 2002.
  76. Eric T. Boder, Katarina D. Midelfort, and K. Dane Wittrup. “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.” Proceedings of the National Academy of Sciences: 97(20), 10701-10705, 2000.
  77. Nedim Ince, Suzanne de la Monte, Jack R. Wands. “Overexpression of Human Aspartyl (Asparaginyl) β-Hydroxylase is associated with malignant transformation.” Cancer Research: 60, 1261-1266, 2000.

.